Abstract:Background Reprogramming of amino acid metabolism is critical for tumor growth. We have reported that upregulation of pyrroline-5-carboxylate reductase 1 (PYCR1), a key enzyme in mitochondrial proline anabolism, contributes to gastric cancer (GC) progression and indicates poor survival. However, the PYCR1 expression profile in GC subtypes and the underlying mechanisms behind its upregulation, as well as the promotion of GC progression are not well-studied. Methods PYCR1 expression profiles in GC subtypes and stages of gastric carcinogenesis were assessed in different cohorts. Genetic alterations and epigenetic modulation in PYCR1 regulation were investigated in tumor tissues and GC cell lines. The effect of PYCR1 on GC progression was further investigated from the perspectives of mitochondrial function and intracellular metabolism. Results PYCR1 expression was significantly higher in intestinal-type GC and associated molecular subtypes in two independent GC cohorts. During the Correa cascade of gastric carcinogenesis, PYCR1 was continuously increased from normal gastric tissues to atrophic gastritis with or without intestinal metaplasia, through to dysplasia, and finally to cancerous lesions. Hypomethylation and p300-mediated H3K27ac acetylation activation in PYCR1 promotor synergistically facilitated PYCR1 transcription. PYCR1 depletion or overexpression attenuated or promoted GC cell proliferation, but did not have any effect on the cell cycle. PYCR1 inhibition decreased mitochondrial DNA copy number in GC cells, but had no effect on mitochondrial membrane potential, mitochondrial mass and oxidative stress response. Detection of intracellular metabolite profiles revealed that PYCR1 depletion had a significant effect on intracellular purine metabolism (hypoxanthine, inosine and adenosine monophosphate), which was associated with cell growth inhibition. Furthermore, depletion of PYCR1 restored mitochondrial networking via enhancing mitochondrial fusion, leading to inhibition of cell proliferation. Consistently, pharmacological enhancement with Mdivi-1 of mitochondrial fusion also brought about the similar effects. Conversely, PYCR1 overexpression promoted mitochondrial fission, contributing to tumor growth. Conclusions PYCR1 overexpression was heterogeneous in different GC subtypes, and an increase in PYCR1 was an early event in the multistep of gastric carcinogenesis. Epigenetic modulation synergistically contributes to PYCR1 upregulation in GC, resulting in tumor progression via enhancing mitochondrial fission and coupling with purine metabolic reprogramming. Collectively, PYCR1 might be a promising therapeutic target for GC.

Protein Arginine Methyltransferase 5-Mediated Epigenetic Silencing of IRX1 Contributes to Tumorigenicity and Metastasis of Gastric Cancer

PRMT1 Promotes the Proliferation and Metastasis of Gastric Cancer Cells by Recruiting MLXIP for the Transcriptional Activation of the Β-Catenin Pathway

PRMT5-dependent Transcriptional Repression of C-Myc Target Genes Promotes Gastric Cancer Progression.

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

XRCC1 Downregulated Through Promoter Hypermethylation is Involved in Human Gastric Carcinogenesis

Oncogenic miR-544 is an important molecular target in gastric cancer.

Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression

IDDF2022-ABS-0083 Epigenetic Induction of Mitochondrial Proline Synthase PYCR1 Promotes Gastric Cancer Progression by Regulating Mitochondrial Dynamics and Purine Metabolism

PRMT6 Promotes the Immune Evasion of Gastric Cancer by Upregulating ANXA1

SIRT1 Suppresses the Migration and Invasion of Gastric Cancer by Regulating ARHGAP5 Expression

PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression

Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling

The RNA M6a Reader IGF2BP3 Regulates NFAT1/IRF1 Axis-Mediated Anti-Tumor Activity in Gastric Cancer

The mechanism of RGS5 regulating gastric cancer mismatch repair protein

KRAB Zinc-Finger Protein 382 Regulates Epithelial-Mesenchymal Transition and Functions As a Tumor Suppressor, but is Silenced by CpG Methylation in Gastric Cancer

The m6A reader IGF2BP3 Facilitates Gastric Cancer Progression Through Activating EMT via Upregulating MYC mRNA Stability

UHRF1 Promotes Proliferation of Gastric Cancer Via Mediating Tumor Suppressor Gene Hypermethylation.

MicroRNA-501-3p targeting TM4SF1 facilitates tumor-related behaviors of gastric cancer cells via EMT signaling pathway

Homeobox Gene Irx1 Is A Tumor Suppressor Gene In Gastric Carcinoma

RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling